BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.

MLA

Fiskus, Warren, et al. “BRG1/BRM Inhibitor Targets AML Stem Cells and Exerts Superior Preclinical Efficacy Combined with BET or Menin Inhibitor.” Blood, vol. 143, no. 20, May 2024, pp. 2059–72. EBSCOhost, https://doi.org/10.1182/blood.2023022832.

APA

Fiskus, W., Piel, J., Collins, M., Hentemann, M., Cuglievan, B., Mill, C. P., Birdwell, C. E., Das, K., Davis, J. A., Hou, H., Jain, A., Malovannaya, A., Kadia, T. M., Daver, N., Sasaki, K., Takahashi, K., Hammond, D., Reville, P. K., Wang, J., … Bhalla, K. N. (2024). BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor. Blood, 143(20), 2059–2072. https://doi.org/10.1182/blood.2023022832

Chicago

Fiskus, Warren, Jessica Piel, Mike Collins, Murphy Hentemann, Branko Cuglievan, Christopher P Mill, Christine E Birdwell, et al. 2024. “BRG1/BRM Inhibitor Targets AML Stem Cells and Exerts Superior Preclinical Efficacy Combined with BET or Menin Inhibitor.” Blood 143 (20): 2059–72. doi:10.1182/blood.2023022832.